Last reviewed · How we verify

NCT06052358

Left Atrial Appendage Closure With WATCHMAN FLX Device in Recurrent Gastrointestinal Bleeding: The GI-FLX Registry

Terminated Last updated 4 September 2025
What this trial tests

trial testing LAAC with Watchman FLX device in Atrial Fibrillation in 73 participants. Terminated before completion.

Timeline
23 August 2023
Primary endpoint
11 June 2025
11 June 2025

Quick facts

Lead sponsorKansas City Heart Rhythm Research Foundation
StatusTerminated
Study typeOBSERVATIONAL
Enrollment73
Start date23 August 2023
Primary completion11 June 2025
Estimated completion11 June 2025
Sites4 locations across United States

Drugs / interventions tested

Conditions studied

Sponsor

Kansas City Heart Rhythm Research Foundation

Who can join

18 and older, any sex, with Atrial Fibrillation or GI Bleeding. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The GI-FLX Registry is intended to create a registry of patients with a history of Atrial Fibrillation (AF) and Gastrointestinal (GI) bleed who will receive Left Atrial Appendage Closure (LAAC) with WATCHMAN FLX device and compare to patients with AF and GI bleed who do not have LAAC. The GI-FLX Registry will be a multi-center, non-randomized registry. Approximately 250 prospective patients will be enrolled at all 4 sites. Historical cohort of 250 patients after propensity score matching with WATCHMAN-FLX arm will be included in the final analysis.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Atrial Fibrillation

Currently open trials in the same condition.

Other Kansas City Heart Rhythm Research Foundation trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06052358.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing